A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Non-small-cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Cervical Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma

Interventions

DRUG: ALE.P02

Sponsor

Alentis Therapeutics AG